Reprint

What SARS-CoV-2 Variants Have Taught Us: Evolutionary Challenges of RNA Viruses

Edited by
April 2024
366 pages
  • ISBN978-3-0365-9831-4 (Hardback)
  • ISBN978-3-0365-9832-1 (PDF)

This is a Reprint of the Special Issue What SARS-CoV-2 Variants Have Taught Us: Evolutionary Challenges of RNA Viruses that was published in

Biology & Life Sciences
Medicine & Pharmacology
Public Health & Healthcare
Summary

RNA viruses have a rapid pace of evolutionary change. Mutations in RNA viral genomes occur at a pace that greatly exceeds that observed in other organisms and determine much of their evolutionary “behavior”. For instance, RNA viruses have a great ability to cross species barriers and, hence, emerging new human and animal viruses. Indeed, emerging RNA viruses are currently the biggest health threat to humankind to emerge in a very long time. Thus, it is crucial at this time to shed some light on how the evolutionary behavior of RNA viruses shapes their epidemiolocal, fitness, and pathological features. This will contribute toward a better understanding of how to deal with these threats.

Format
  • Hardback
License and Copyright
© 2024 by the authors; CC BY-NC-ND license
Keywords
COVID-19; Omicron; sub-lineages; Ecuador; SARS-CoV-2 variants; Omicron; pseudovirus; neutralization assay; convalescent plasma; COVID-19; SARS-CoV-2; chicken; passive immunization; antibodies; neutralizing antibodies; egg; SARS-CoV-2; Omicron; BA.2; BA.5; symptoms; Germany; COVID-19; impact; variant of concern; SARS-CoV-2; SARS-CoV-2 variants; phylogenetic analysis; COVID-19; SARS-CoV-2; nucleocapsid; protein localization; antibody therapy; severe acute respiratory syndrome coronavirus 2; high-resolution melting; Omicron subvariant; BA.5; F486V mutation; SARS-CoV-2; Omicron; COVID-19; evolution; receptor binding domain; T-cell epitope; spike protein; drug; SARS-CoV-2; spike protein; B.1.620; R.1; cell entry; neutralization; antibody evasion; ACE2 binding; molecular modeling; mutation analysis; nucleotide diversity; RNA secondary structure; VOCs; COVID-19; SARS-CoV-2; variants; infection control; SARS-CoV-2; Omicron; spike protein RBD; heparin; pentosan polysulfate; mucopolysaccharide polysulfate; COVID-19; omicron; delta; immunocompromised host; hospitalization; RNA virus; evolution; quasispecies; mutation; recombination; coronavirus; SARS-CoV-2; SARS-CoV-2; virus adaptation; persistent infection; SARS-CoV-2; COVID-19; N-terminal domain; receptor binding domain; LRRC15; leucine rich repeat containing 15; neuropilin-1; NRP-1; mutations; RNA viruses; SARS-CoV-2 variants; host immunity; adaptation; viral escape; Omicron: sub-lineages; transmission and infection; disease severity; COVID-19; SARS-CoV-2; peptide microarray; humoral immunity; IgA; IgG; epitope mapping; SARS-CoV-2 variant; pandemic; vaccine; antiviral; SARS-CoV-2; HIV-1; MERS-CoV; monkeypox virus; influenza virus; lipid raft; ganglioside; neutralization; electrostatic surface potential; SARS-CoV-2; Omicron; variants; evolution; South America; dynamics; BA.1; BA.2; BA.4; BA.5; COVID-19; vaccines; booster vaccines doses; effectiveness; COVID-19-related disease; SARS CoV-2 antibody; SARS-CoV-2; COVID-19; delta; VOC; RT-qPCR; surveillance; n/a

Related Books

December 2020

Vaccines against RNA Viruses

Medicine & Pharmacology
March 2024

Molecular Biology of RNA Viruses

Biology & Life Sciences
...
February 2024

RNA Viruses and Antibody Response

Biology & Life Sciences
April 2020

New Insights into Parvovirus Research

Biology & Life Sciences
...